Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2317 - The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Sang-Hee Cho

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

S. Cho1, H. Shim1, J.E. Hwang1, W. Bae1, I.J. Chung2

Author affiliations

  • 1 Hemato-oncology, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 519-809 - Hwasun/KR
  • 2 Hemato-oncology, Chonnam National University Hwasun Hospital, 519-763 - Hwasun/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2317

Background

Tumors expressing programmed death ligand 1 (PD-L1) can render immune inactivated via triggering of PD-1 receptor on T cells with various pathways. Based on this mechanism, the blockade PD-1/PD-L1 pathway has been used as a therapeutic target for metastatic CRC. In the present study, we evaluated the prognostic role of PD-L1 expression associated with microsatellite status in surgically resected stage III colon cancer patients.

Methods

PD-L1 expression was performed by immunohistochemistry from 182 stage III colon cancer patients after curative resection. The percentage of PD-L1 positive tumor cells and staining intensity were evaluated and categorized as ‘strong’ or ‘weak’ positive group. Clinical and histopathologic parameters including of MSI status and survival outcomes were analyzed with IDO expression which stands for the suppressive immune environment.

Results

Strong PD-L1 expression was observed in 29% of all patients. Perineural invasion and lymphocyte response were more frequently shown in strong expression of PD-L1 grop. Among resected patients, MSI was shown in 23 patients (12%). Although there was no significant difference between microsatellite status and PD-L1 expression, strong PD-L1 tended to better overall survival in microsatellite stable (MSS) colon cancer (P = 0.056). In contrast, strong PD-L1 expression was significantly correlated with worse DFS (P = 0.001) and OS (P < 0.001) than weak PD-L1 expression group in microsatellite instability (MSI) patients, regardless of adjuvant chemotherapy. Also, the strong IDO expression was tended to be more frequently shown in strong PD-L1 expression (36.4%) group than weak PD-L1 expression (14.3%) group in MSI patients.

Conclusions

The expression of PD-L1 is differently affected on the survival outcomes according to the status of microsatellite. There is no significant relationship between the expression of PD-L1 and prognosis in MSS stage III colon cancer patients. However, in MSI colon cancer which has been well known as a highly immunogenic property, strong PD-L1 expression is significantly associated with poor prognosis on survival outcomes reflecting the immunosuppressive microenvironment in curative resected stage III colon cancer patient.

Clinical trial identification

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.